SMMT insider transaction filings
Summit Therapeutics Inc. — 30 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-12. Screen SMMT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-12 | 4 | Zanganeh Mahkam — Co-Chief Executive Officer, Director, 10% owner | Purchase (P): 3,810,000 @ $13.12 | EDGAR |
| 2026-06-12 | 4 | DUGGAN ROBERT W — Co-Chief Executive Officer, Director, 10% owner | Purchase (P): 3,810,000 @ $13.12 | EDGAR |
| 2026-06-04 | 4 | Soni Manmeet Singh — COO and CFO, Director | Purchase (P): 25,000 @ $14.46 · Purchase (P): 25,000 @ $14.43 | EDGAR |
| 2026-06-04 | 4 | Zanganeh Mahkam — Co-Chief Executive Officer, Director, 10% owner | Purchase (P): 100,000 @ $14.60 | EDGAR |
| 2026-06-04 | 4 | DUGGAN ROBERT W — Co-Chief Executive Officer, Director, 10% owner | Purchase (P): 100,000 @ $14.60 | EDGAR |
| 2026-01-12 | 4 | Anand Bhaskar — Chief Accounting Officer | Grant/award (A): 30,000 (derivative) | EDGAR |
| 2026-01-06 | 4 | Xia Yu — Director | Grant/award (A): 35,000 (derivative) | EDGAR |
| 2026-01-06 | 4 | Cesano Alessandra — Director | Grant/award (A): 35,000 (derivative) · Grant/award (A): 3,219 (derivative) @ $8.76 | EDGAR |
| 2026-01-06 | 4 | Clark Kenneth A — Director | Grant/award (A): 35,000 (derivative) · Grant/award (A): 17,796 (derivative) @ $8.76 | EDGAR |
| 2026-01-06 | 4 | Zanganeh Mahkam — Co-Chief Executive Officer, Director, 10% owner | Grant/award (A): 11,232 (derivative) @ $8.76 | EDGAR |
| 2026-01-06 | 4 | Booth Robert F. — Director | Grant/award (A): 35,000 (derivative) · Grant/award (A): 7,180 (derivative) @ $8.76 | EDGAR |
| 2026-01-06 | 4 | Huber Jeff — Director | Grant/award (A): 35,000 (derivative) · Grant/award (A): 9,885 (derivative) @ $8.76 | EDGAR |
| 2026-01-06 | 4 | Ronaghi Mostafa — Director | Grant/award (A): 35,000 (derivative) | EDGAR |
| 2026-01-06 | 4 | DUGGAN ROBERT W — Co-Chief Executive Officer, Director, 10% owner | Grant/award (A): 11,232 (derivative) @ $8.76 | EDGAR |
| 2025-10-23 | 4 | Xia Yu — Director | Purchase (P): 533,617 @ $18.74 | EDGAR |
| 2025-10-23 | 4 | Anand Bhaskar — Chief Accounting Officer | Grant/award (A): 26,680 @ $18.74 | EDGAR |
| 2025-10-23 | 4 | Soni Manmeet Singh — COO and CFO, Director | Grant/award (A): 53,361 @ $18.74 | EDGAR |
| 2025-10-23 | 4 | Zanganeh Mahkam — Co-Chief Executive Officer, Director, 10% owner | Grant/award (A): 266,808 @ $18.74 · Purchase (P): 26,680 @ $18.74 · Grant/award (A): 13,980,789 @ $18.74 | EDGAR |
| 2025-10-23 | 4 | DUGGAN ROBERT W — Co-Chief Executive Officer, Director, 10% owner | Grant/award (A): 13,980,789 @ $18.74 · Grant/award (A): 266,808 @ $18.74 · Purchase (P): 26,680 @ $18.74 | EDGAR |
| 2025-09-19 | 4 | Anand Bhaskar — Chief Accounting Officer | Grant/award (A): 50,000 (derivative) | EDGAR |
| 2025-09-11 | 4 | Zanganeh Mahkam — Co-Chief Executive Officer, Director, 10% owner | Purchase (P): 333,394 @ $17.68 · Purchase (P): 5,000 @ $18.07 | EDGAR |
| 2025-09-11 | 4 | DUGGAN ROBERT W — Co-Chief Executive Officer, Director, 10% owner | Purchase (P): 333,394 @ $17.68 · Purchase (P): 5,000 @ $18.07 | EDGAR |
| 2025-06-02 | 4 | Zanganeh Mahkam — Co-Chief Executive Officer, Director, 10% owner | Option exercise (M): 74,545 @ $2.64 · Option exercise (M): 74,545 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | DUGGAN ROBERT W — Co-Chief Executive Officer, Director, 10% owner | Option exercise (M): 74,545 @ $2.64 · Option exercise (M): 74,545 (derivative) @ $0 | EDGAR |
| 2025-05-01 | 4 | Anand Bhaskar — Chief Accounting Officer | Grant/award (A): 600,000 (derivative) · Grant/award (A): 75,000 (derivative) | EDGAR |
| 2025-05-01 | 4 | Soni Manmeet Singh — COO and CFO, Director | Grant/award (A): 11,200,000 (derivative) | EDGAR |
| 2025-05-01 | 4 | Zanganeh Mahkam — Co-Chief Executive Officer, Director, 10% owner | Grant/award (A): 1,040,000 (derivative) · Grant/award (A): 400,000 (derivative) · Grant/award (A): 9,590,558 (derivative) | EDGAR |
| 2025-05-01 | 4 | DUGGAN ROBERT W — Co-Chief Executive Officer, Director, 10% owner | Grant/award (A): 1,040,000 (derivative) · Grant/award (A): 400,000 (derivative) · Grant/award (A): 9,590,558 (derivative) | EDGAR |
| 2025-04-09 | 4 | Zanganeh Mahkam — Co-Chief Executive Officer, Director, 10% owner | Option exercise/expiry (X): 3,985,055 @ $1.58 · Option exercise/expiry (X): 3,985,055 (derivative) @ $0 | EDGAR |
| 2025-04-09 | 4 | DUGGAN ROBERT W — Co-Chief Executive Officer, Director, 10% owner | Option exercise/expiry (X): 3,985,055 @ $1.58 · Option exercise/expiry (X): 3,985,055 (derivative) @ $0 | EDGAR |
Recent 8-K events — Summit Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-11 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-06-03 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-23 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SMMT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →